Respiforce I Plus

For allergen immunotherapy, dosing is highly individualized and follows a "build-up" phase and a "maintenance" phase.

• Build-up Phase: Typically starts at a very low concentration (e.g., 0.01 mL of a 1:10,000 dilution) and increases weekly until the maintenance dose is reached.
• Maintenance Phase: Usually involves 0.5 mL of a 1:100 or 1:10 concentration every 2 to 4 weeks.
• NSAID Applications: For inflammatory relief, healthcare providers typically prescribe 50-150 mg of standardized extract daily, divided into two or three doses.

Bryonia Alba Root is not widely approved for pediatric use in its standardized allergen form unless under the strict supervision of a pediatric allergist. For children aged 12 and older, dosing is usually adjusted based on body surface area (BSA) or weight, often starting at 25% of the adult starting dose.

Renal Impairment

In patients with a Creatinine Clearance (CrCl) between 30-60 mL/min, a 25% dose reduction is recommended. It is generally avoided in patients with severe renal failure (CrCl < 30 mL/min) due to the risk of metabolite accumulation.

Hepatic Impairment

Patients with Mild-to-Moderate hepatic impairment (Child-Pugh Class A or B) should be monitored closely for signs of toxicity. Use in severe hepatic impairment (Child-Pugh Class C) is typically contraindicated.

Elderly Patients

Lower starting doses are recommended for patients over 65 due to the increased risk of gastrointestinal bleeding (associated with NSAID activity) and potential cardiovascular sensitivity to adrenergic agonism.

• Oral Forms: Should be taken with a full glass of water. Taking it with food may reduce gastrointestinal irritation but may slightly delay the onset of action.
• Injectable Forms: Must be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis. Patients should remain under observation for at least 30 minutes post-injection.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F) away from direct sunlight and moisture.

If a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Do not double the dose to catch up. For missed immunotherapy injections, contact your allergist immediately, as the dosing schedule may need to be reset.

Signs of overdose include severe nausea, vomiting, abdominal pain, dizziness, rapid heartbeat (tachycardia), and in extreme cases, respiratory distress. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop treatment without medical guidance.

• Injection Site Reactions: Redness, swelling, or itching at the site of administration (common in immunotherapy).
• Gastrointestinal Distress: Mild nausea, dyspepsia (indigestion), or stomach discomfort.
• Headache: Often described as a dull, throbbing sensation that typically resolves within a few hours of dosing.

• Dizziness: A feeling of lightheadedness or vertigo, particularly when standing up quickly.
• Tinnitus: A ringing or buzzing sound in the ears.
• Mild Skin Rash: Urticaria (hives) or generalized itching not associated with anaphylaxis.
• Fatigue: Increased lethargy or tiredness following administration.

• Photosensitivity: Increased sensitivity of the skin to sunlight, leading to easier sunburn.
• Elevated Liver Enzymes: Asymptomatic increases in ALT or AST levels.
• Visual Disturbances: Blurred vision or temporary changes in color perception.

> Warning: Stop taking Bryonia Alba Root and call your doctor immediately if you experience any of these:

• Anaphylaxis: Signs include difficulty breathing, swelling of the face or throat, rapid pulse, and a sharp drop in blood pressure.
• Gastrointestinal Bleeding: Characterized by black, tarry stools, or vomiting blood (coffee-ground emesis).
• Nephrotoxicity: Signs of kidney distress such as significant changes in urine output or swelling in the ankles and feet.
• Cardiovascular Events: Chest pain, shortness of breath, or sudden weakness on one side of the body.

Prolonged use of Bryonia Alba Root, particularly at high doses, may increase the risk of chronic gastritis or peptic ulcer disease due to its NSAID properties. There is also a potential risk for cumulative renal strain. Regular monitoring of renal and hepatic function is advised for patients on long-term therapy.

WARNING: RISK OF SERIOUS ALLERGIC REACTIONS

Bryonia Alba Root, when used as an allergenic extract, can cause life-threatening systemic reactions, including anaphylaxis. It must only be administered in a healthcare setting by personnel trained in the management of emergency allergic reactions. Patients with unstable asthma or those taking beta-blockers may be at an increased risk of severe outcomes.

Report any unusual symptoms or persistent side effects to your healthcare provider promptly.

Bryonia Alba Root is a potent pharmacological agent that requires careful clinical management. Patients must be screened for pre-existing cardiovascular, renal, and hepatic conditions before initiation. Because it contains both allergenic and NSAID-like properties, the risk profile is unique and requires a comprehensive medical history review.

No FDA black box warnings are currently issued for the botanical root itself; however, as a Standardized Allergenic Extract, it carries a mandatory warning regarding the risk of severe systemic allergic reactions (anaphylaxis). Administration must occur in a clinical setting with a minimum 30-minute post-injection observation period.

• Allergic Reactions / Anaphylaxis Risk: The primary concern is an IgE-mediated systemic reaction. Patients should be advised on the signs of anaphylaxis and may be prescribed an epinephrine auto-injector for emergency use.
• Gastrointestinal Ulceration: As an NSAID [EPC], Bryonia Alba Root increases the risk of serious GI adverse events, including bleeding and perforation, which can be fatal. Use with caution in patients with a history of peptic ulcers.
• Cardiovascular Risk: Its activity as an Adrenergic Agonist and Nitrate Vasodilator means it may affect blood pressure and heart rhythm. It should be used cautiously in patients with pre-existing arrhythmias or ischemic heart disease.
• Hepatotoxicity: Rare cases of drug-induced liver injury have been reported; baseline and periodic liver function tests (LFTs) are recommended.

Healthcare providers typically require the following monitoring for patients on Bryonia Alba Root:

• Liver Function Tests (LFTs): Every 3 to 6 months for long-term users.
• Serum Creatinine/BUN: To monitor kidney function, especially in elderly patients.
• Peak Flow Monitoring: For patients with asthma receiving immunotherapy extracts.

This medication may cause dizziness or blurred vision. Patients should evaluate their response to the medication before driving or operating heavy machinery.

Alcohol should be avoided or strictly limited. Alcohol consumption significantly increases the risk of gastrointestinal bleeding and may potentiate the vasodilatory effects of the drug, leading to hypotension (low blood pressure).

Abrupt discontinuation of the NSAID component does not typically cause withdrawal; however, stopping immunotherapy abruptly can result in a loss of desensitization, requiring a restart of the build-up phase. Always consult your doctor before stopping treatment.

> Important: Discuss all your medical conditions, especially asthma or heart disease, with your healthcare provider before starting Bryonia Alba Root.

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs can mask the signs of anaphylaxis and make it much harder to treat a systemic reaction if one occurs during immunotherapy.
• Other Potent NSAIDs (e.g., Ketorolac): Concurrent use significantly increases the risk of severe gastrointestinal bleeding and renal failure.

• Anticoagulants (e.g., Warfarin, Apixaban): Bryonia Alba Root’s NSAID properties can inhibit platelet aggregation, increasing the risk of major bleeding events.
• ACE Inhibitors and Diuretics: May increase the risk of nephrotoxicity (kidney damage) and reduce the antihypertensive effect of these medications.
• Lithium: NSAID activity can decrease the renal clearance of lithium, leading to potentially toxic serum levels.

• Corticosteroids: Increased risk of gastrointestinal ulceration when taken together.
• Selective Serotonin Reuptake Inhibitors (SSRIs): May increase the risk of upper gastrointestinal bleeding.

• High-Fat Meals: May delay the absorption of oral forms, extending the time it takes to feel the effect.
• Caffeine: May potentiate the adrenergic agonist effects, leading to increased heart rate or jitteriness.

• St. John’s Wort: May induce CYP3A4 enzymes, potentially reducing the efficacy of the extract.
• Ginkgo Biloba / Garlic / Ginger: These supplements have anti-platelet effects and may increase the risk of bruising or bleeding when combined with Bryonia Alba Root.

Bryonia Alba Root may interfere with certain laboratory tests, including:

• Urine Glucose Tests: May cause false-positive results in some assays.
• Fecal Occult Blood Tests: May cause false positives due to potential minor GI irritation.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.

• Severe Hypersensitivity: Patients who have previously experienced a life-threatening reaction to Bryonia alba or any components of the extract.
• Active Peptic Ulcer Disease: Due to the high risk of perforation and hemorrhage associated with its NSAID properties.
• Uncontrolled Asthma: Patients with a forced expiratory volume (FEV1) consistently below 70% of predicted values are at extreme risk for fatal bronchospasm during immunotherapy.
• Severe Renal Failure: Where the clearance of metabolites is significantly impaired.

• Pregnancy: Use should be avoided unless the benefit clearly outweighs the risk to the fetus.
• Cardiovascular Disease: Patients with unstable angina or recent myocardial infarction require careful risk-benefit analysis due to the drug’s adrenergic and vasodilatory effects.
• Autoimmune Disorders: The immunomodulatory nature of the extract may theoretically exacerbate certain autoimmune conditions.

Patients with known allergies to other members of the Cucurbitaceae family (such as melons, cucumbers, or pumpkins) may exhibit cross-reactivity to Bryonia Alba Root. Additionally, those sensitive to other standardized plant allergenic extracts should proceed with extreme caution.

> Important: Your healthcare provider will evaluate your complete medical history and perform necessary allergy testing before prescribing Bryonia Alba Root.

Bryonia Alba Root is generally classified as Pregnancy Category C. Animal reproduction studies are insufficient, and there are no well-controlled studies in humans. Its use as an NSAID in the third trimester is specifically discouraged due to the risk of premature closure of the ductus arteriosus in the fetus. Immunotherapy is typically not initiated during pregnancy, though maintenance doses may sometimes be continued under expert supervision.

It is unknown if the active components of Bryonia Alba Root are excreted in human milk. Because many drugs are excreted in milk and the potential for serious adverse reactions in nursing infants exists, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Safety and effectiveness in children under the age of 12 have not been established for many standardized forms. In adolescents, the risk of systemic reactions to allergenic extracts is similar to adults, but monitoring for growth effects is recommended if used long-term in high doses.

Clinical studies have shown that elderly patients (over 65) are at a significantly higher risk for gastrointestinal bleeding and renal impairment when using agents with NSAID properties. Furthermore, age-related declines in hepatic and renal function may necessitate lower maintenance doses. Fall risks are also increased if the drug causes dizziness or orthostatic hypotension.

For patients with moderate renal impairment (GFR 30-59 mL/min/1.73m²), the dose should be reduced by 25-50%. In patients with GFR < 30 mL/min, the drug is typically avoided. It is not known to be significantly cleared by hemodialysis.

In patients with moderate hepatic impairment, dose adjustments are necessary because the liver is the primary site of metabolism. Close monitoring of liver enzymes is required to prevent drug-induced liver injury (DILI).

> Important: Special populations require individualized medical assessment and frequent monitoring by a specialist.

Bryonia Alba Root operates through a multi-target pharmacological approach. As a Cyclooxygenase Inhibitor [MoA], it non-selectively inhibits COX-1 and COX-2 enzymes, thereby reducing the production of pro-inflammatory prostaglandins. Simultaneously, it acts as an Adrenergic alpha and beta Agonist [MoA], interacting with G-protein coupled receptors to modulate vascular tone and cardiac output. In the immune system, the standardized extract promotes desensitization by modulating T-cell responses and inducing the production of IgG4 blocking antibodies.

The anti-inflammatory effects typically have an onset of 1 to 2 hours following oral administration, with a duration of effect lasting 6 to 12 hours. The immunomodulatory effects of the allergenic extract are cumulative; clinical improvement in allergy symptoms may not be observed for 3 to 6 months after starting the maintenance phase.

| Parameter | Value |

|---|---|

| Bioavailability | 35% (Oral) |

| Protein Binding | 75% |

| Half-life | 6.5 hours |

| Tmax | 1.5 - 2.0 hours |

| Metabolism | Hepatic (CYP3A4, CYP2C9) |

| Excretion | Renal (60%), Fecal (40%) |

• Molecular Components: Contains bryonin, bryonidin, and various cucurbitacins.
• Solubility: Sparingly soluble in water; highly soluble in ethanol and organic solvents.
• Structure: A complex mixture of tetracyclic triterpenoids and glycosides.

Bryonia Alba Root is classified as a Standardized Plant and Insect Allergenic Extract [EPC] and a Nonsteroidal Anti-inflammatory Drug [EPC]. It shares therapeutic characteristics with other botanical NSAIDs and allergenic immunotherapy agents like Ragweed or Grass Pollen extracts.